Aytu BioPharma, Inc. (LON:0A8M)
2.200
+0.520 (30.95%)
At close: May 16, 2025
Aytu BioPharma Balance Sheet
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2016 - 2020 |
Cash & Equivalents | 30.95 | 20.01 | 22.99 | 19.36 | 49.65 | Upgrade |
Cash & Short-Term Investments | 30.95 | 20.01 | 22.99 | 19.36 | 49.65 | Upgrade |
Cash Growth | 54.71% | -12.96% | 18.72% | -61.01% | 3.26% | Upgrade |
Receivables | 31.16 | 23.53 | 28.73 | 21.71 | 28.18 | Upgrade |
Inventory | 11.43 | 12.14 | 8.51 | 10.85 | 16.34 | Upgrade |
Prepaid Expenses | 5.64 | 5.1 | 5.43 | 7.38 | 9.78 | Upgrade |
Restricted Cash | - | - | - | - | 0.25 | Upgrade |
Other Current Assets | - | 1.12 | 5.43 | 0.63 | 1.04 | Upgrade |
Total Current Assets | 79.18 | 61.89 | 71.08 | 59.93 | 105.23 | Upgrade |
Property, Plant & Equipment | 1.59 | 1.52 | 3.61 | 6.3 | 8.7 | Upgrade |
Goodwill | - | - | - | - | 65.8 | Upgrade |
Other Intangible Assets | 42.2 | 52.45 | 57.44 | 70.63 | 85.46 | Upgrade |
Long-Term Deferred Tax Assets | 0.25 | 0.76 | 1.38 | - | - | Upgrade |
Other Long-Term Assets | 0.95 | 1.47 | 2.96 | 0.77 | 0.47 | Upgrade |
Total Assets | 124.18 | 118.1 | 136.46 | 137.62 | 265.67 | Upgrade |
Accounts Payable | 10.6 | 10.31 | 12.55 | 10.99 | 19.26 | Upgrade |
Accrued Expenses | 15.26 | 22.26 | 24.54 | 25.71 | 30.72 | Upgrade |
Short-Term Debt | 9.06 | 2.4 | 1.56 | 3.81 | 7.93 | Upgrade |
Current Portion of Long-Term Debt | 1.86 | 1.86 | - | - | 16.57 | Upgrade |
Current Portion of Leases | 0.14 | 0.71 | 1.34 | 0.1 | 0.1 | Upgrade |
Other Current Liabilities | 26.15 | 24.69 | 29.02 | 23.84 | 34.86 | Upgrade |
Total Current Liabilities | 63.06 | 62.23 | 69.02 | 64.44 | 109.44 | Upgrade |
Long-Term Debt | 10.9 | 10.88 | 14.71 | 14.2 | - | Upgrade |
Long-Term Leases | 0.99 | 0.58 | 0.83 | 0.08 | 0.18 | Upgrade |
Long-Term Deferred Tax Liabilities | 0.25 | 0.76 | 1.38 | - | - | Upgrade |
Other Long-Term Liabilities | 30.02 | 15.94 | 11.17 | 14.59 | 18.48 | Upgrade |
Total Liabilities | 105.21 | 90.38 | 97.11 | 93.32 | 128.1 | Upgrade |
Common Stock | 0 | 0 | 0 | - | 0 | Upgrade |
Additional Paid-In Capital | 352.5 | 347.69 | 343.49 | 331.39 | 315.86 | Upgrade |
Retained Earnings | -333.54 | -319.97 | -304.13 | -287.08 | -178.3 | Upgrade |
Total Common Equity | 18.97 | 27.72 | 39.36 | 44.31 | 137.57 | Upgrade |
Shareholders' Equity | 18.97 | 27.72 | 39.36 | 44.31 | 137.57 | Upgrade |
Total Liabilities & Equity | 124.18 | 118.1 | 136.46 | 137.62 | 265.67 | Upgrade |
Total Debt | 22.94 | 16.42 | 18.45 | 18.19 | 24.78 | Upgrade |
Net Cash (Debt) | 8.02 | 3.59 | 4.53 | 1.17 | 24.87 | Upgrade |
Net Cash Growth | 123.38% | -20.87% | 286.86% | -95.29% | -46.03% | Upgrade |
Net Cash Per Share | 1.28 | 0.65 | 1.36 | 0.80 | 29.70 | Upgrade |
Filing Date Shares Outstanding | 9.91 | 6.17 | 5.53 | 3.12 | 1.38 | Upgrade |
Total Common Shares Outstanding | 8.98 | 5.97 | 5.52 | 1.93 | 1.37 | Upgrade |
Working Capital | 16.12 | -0.34 | 2.06 | -4.51 | -4.2 | Upgrade |
Book Value Per Share | 2.11 | 4.64 | 7.13 | 22.97 | 100.08 | Upgrade |
Tangible Book Value | -23.24 | -24.74 | -18.08 | -26.32 | -13.7 | Upgrade |
Tangible Book Value Per Share | -2.59 | -4.14 | -3.28 | -13.65 | -9.97 | Upgrade |
Machinery | 1.08 | 2.78 | 4.29 | 4.45 | 5 | Upgrade |
Construction In Progress | - | - | 0.11 | - | 0.2 | Upgrade |
Leasehold Improvements | 0.16 | 0.04 | 1 | 1 | 0.96 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.